
|Articles|October 1, 2003
New Products & Services
Once-daily quinolone gains new urology indications: West Haven, CT-Bayer Pharmaceuticals has received FDA approval to market its once-daily, extended-release fluoroquinolone, ciprofloxacin (Cipro XR), for two new indications: complicated urinary tract infections and acute uncomplicated pyelonephritis.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC
2
SYNC-T demonstrates high bone metastasis resolution in phase 1 cohort
3
Choosing salvage therapy after prostate cancer focal ablation
4
NDV-01 produces robust 9-month results in high-risk NMIBC
5


















